[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7936 Introduced in House (IH)]

<DOC>






119th CONGRESS
  2d Session
                                H. R. 7936

  To amend the Energy Policy Act of 2005 to support the development, 
demonstration, and commercial application of biotechnology products to 
          increase energy resiliency, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 16, 2026

   Mr. Baird (for himself, Ms. Houlahan, Mrs. Bice, and Mr. Khanna) 
 introduced the following bill; which was referred to the Committee on 
                     Science, Space, and Technology

_______________________________________________________________________

                                 A BILL


 
  To amend the Energy Policy Act of 2005 to support the development, 
demonstration, and commercial application of biotechnology products to 
          increase energy resiliency, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Bioindustrial Scale-Up for Supply 
Chains and Energy Resiliency Act of 2026''.

SEC. 2. SENSE OF CONGRESS.

    It is the sense of Congress that--
            (1) the biggest roadblock for United States biotechnology 
        innovators to commercialization is proving that their products 
        and processes can scale, thus showing investors a path to 
        financial return;
            (2) the United States faces several main challenges to 
        securing the broad range of infrastructure needed for the 
        breadth of products that biotechnology can make, which are 
        that--
                    (A) the United States lacks sufficient 
                biomanufacturing capacity, including because 
                researchers are generating new products faster than 
                manufacturing capacity is increasing and building new 
                facilities is expensive and time-consuming; and
                    (B) biomanufacturing technologies of the future 
                have yet to mature into routine commercial 
                applications, as current biomanufacturing facilities 
                are generally optimized for 1 type of product and are 
                usually not compatible with other products; and
            (3) to position the United States as a leader in 
        bioindustrial innovation and enable participation in 
        groundbreaking projects through state-of-the-art 
        infrastructure, it is critical to establish technology 
        maturation facilities to provide world-class capabilities.

SEC. 3. BIOINDUSTRIAL SCALE-UP FOR SUPPLY CHAINS AND ENERGY RESILIENCY.

    Section 932 of the Energy Policy Act of 2005 (42 U.S.C. 16232) is 
amended--
            (1) in subsection (a)--
                    (A) by redesignating paragraphs (1) and (2) as 
                paragraphs (5) and (7), respectively;
                    (B) by inserting before paragraph (5) (as so 
                redesignated) the following:
            ``(1) Biobased product.--The term `biobased product' has 
        the meaning given the term in section 9001 of the Farm Security 
        and Rural Investment Act of 2002 (7 U.S.C. 8101).
            ``(2) Bioindustrial manufacturing.--The term `bioindustrial 
        manufacturing' means the use of living organisms, cells, 
        tissues, enzymes, or cell-free systems to produce materials and 
        products for nonpharmaceutical applications.
            ``(3) Biointermediate.--The term `biointermediate' means an 
        intermediate product that is derived from biomass or waste 
        streams, including carbon oxides.
            ``(4) Biomanufacturing.--The term `biomanufacturing' means 
        the use of biological systems to produce goods and services at 
        commercial scale.'';
                    (C) by inserting after paragraph (5) (as so 
                redesignated) the following:
            ``(6) Biotechnology.--The term `biotechnology' means 
        technology that applies to or is enabled by life sciences 
        innovation or product development.''; and
                    (D) by inserting after paragraph (7) (as so 
                redesignated) the following:
            ``(8) Open access.--The term `open access', with respect to 
        infrastructure, data, or research resources, means that those 
        resources are--
                    ``(A) available without licensing or intellectual 
                property barriers; and
                    ``(B) accessible to public and private entities on 
                an equitable basis.
            ``(9) Phytobiome.--The term `phytobiome' means a network of 
        interactions of plants, their associated communities of 
        organisms, and their environmental context.
            ``(10) Technology maturation.--The term `technology 
        maturation' means the development, testing, and scaling of 
        technologies to a level of readiness suitable for 
        commercialization or integration into industrial processes, 
        including activities such as prototyping, pilot-scale testing 
        and demonstration, and early-stage manufacturing and market 
        entry.
            ``(11) Waste stream.--The term `waste stream' includes 
        municipal solid waste, food waste, urban wood waste, food 
        processing and fermentation waste, sewage, biogas, industrial 
        waste gases, carbon oxides, atmospheric oxides, and waste gases 
        that are effluents or byproduct streams from various societal 
        pursuits that are targeted toward disposal, discharge, or 
        burning.''; and
            (2) by inserting after subsection (e) the following:
    ``(f) Bioindustrial Technology Maturation Facilities.--
            ``(1) In general.--Not later than September 30, 2030, the 
        Secretary shall establish not fewer than 2 bioindustrial 
        technology maturation facilities (referred to in this 
        subsection as `covered facilities')--
                    ``(A) to conduct research, development, 
                demonstration, and commercial application to derisk 
                product and process technologies for biotechnology-
                based products relevant to the mission of the 
                Department;
                    ``(B) that are precommercial; and
                    ``(C) that shall operate as user facilities 
                available to governmental and nongovernmental users.
            ``(2) Considerations.--In determining the number, type, and 
        location of covered facilities to establish, the Secretary 
        shall--
                    ``(A) consider--
                            ``(i) the greatest needs of industry and 
                        the gaps in current types of infrastructure;
                            ``(ii) unique capabilities that are 
                        currently not available anywhere in the world;
                            ``(iii) how the covered facilities may--
                                    ``(I) complement current 
                                infrastructure and capabilities, 
                                including infrastructure and 
                                capabilities of--
                                            ``(aa) the Department, 
                                        including National 
                                        Laboratories;
                                            ``(bb) the Department of 
                                        Defense;
                                            ``(cc) the Department of 
                                        Commerce; and
                                            ``(dd) other covered 
                                        facilities; and
                                    ``(II) increase production levels 
                                by functioning as a connected network, 
                                including by ensuring that available 
                                fermentation capacity, including of 
                                covered facilities and facilities of 
                                the Department, covers the full range 
                                needed for precommercial scale-up; and
                            ``(iv) how each covered facility aligns 
                        with regional and local workforce needs, pre-
                        existing capabilities, the skills required for 
                        the proposed biomanufacturing operations, and 
                        the potential for regional and local workforce 
                        development and job creation; and
                    ``(B) ensure that--
                            ``(i) covered facilities are in 
                        geographically diverse locations--
                                    ``(I) to maximize access to 
                                biological material needed as an input 
                                to bioindustrial manufacturing 
                                processes;
                                    ``(II) to leverage available 
                                industrial and academic expertise, 
                                including workforce and human capital; 
                                and
                                    ``(III) to leverage relevant 
                                domestic infrastructure required to 
                                secure supply chains for chemicals and 
                                other materials;
                            ``(ii) covered facilities are complementary 
                        to each other and any other existing related 
                        facilities; and
                            ``(iii) the first covered facility is 
                        planned and built within a 2-year time period, 
                        and the plan for the second and each subsequent 
                        facility is developed while construction occurs 
                        on the earlier planned covered facility.
            ``(3) Activities.--Activities carried out by a covered 
        facility may include the following:
                    ``(A) Conducting pilot and demonstration projects 
                to evaluate bioindustrial manufacturing processes and 
                technologies for customers.
                    ``(B) Conducting activities to scale bioindustrial 
                manufacturing processes and products for scale-up and 
                deployment efforts, and larger, higher, or different 
                levels of production for customers.
                    ``(C) Developing, testing, and implementing 
                applications and tools, including equipment, hardware, 
                software, and algorithms, with industry and academic 
                partners.
                    ``(D) Addressing technical challenges around 
                bioindustrial manufacturing inputs and the technologies 
                and processes that break down or convert biomass, waste 
                streams, and other inputs that are useful to the 
                bioindustrial manufacturing process, biointermediates, 
                or other products.
                    ``(E) Supporting training and workforce development 
                needs in bioindustrial manufacturing.
                    ``(F) Establishing an interoperable, secure, 
                digital infrastructure for collaborative data exchange 
                across entities in the bioindustrial manufacturing 
                community, including government agencies, industry, and 
                academia.
                    ``(G) Developing and implementing digital tools, 
                process security and assurance capabilities, 
                cybersecurity protocols, and best practices for data 
                storage, sharing, and analysis.
                    ``(H) Leveraging data, modeling, and expertise to 
                assist stakeholders in quantifying economic effects of, 
                and future investment strategies relating to, emerging 
                processes and technologies, and incorporating those 
                findings into techno-economic analysis.
                    ``(I) Any other activity that the Secretary 
                determines appropriate.
            ``(4) Collaboration.--In carrying out the activities 
        described in paragraph (3), a covered facility may--
                    ``(A) develop and implement policies to ensure open 
                access to the covered facility for public and private 
                sector entities, with a focus on inclusion of rural 
                communities;
                    ``(B) pursue cost-sharing and cofunding 
                arrangements or opportunities with private sector 
                stakeholders to supplement Federal funding and promote 
                financial sustainability; and
                    ``(C) to maximize the impact of the covered 
                facility, coordinate and collaborate with--
                            ``(i) industry partners, including to 
                        identify priority research, development, and 
                        demonstration needs;
                            ``(ii) other Department facilities, 
                        including National Laboratories;
                            ``(iii) the defense community, including 
                        the Department of Defense and BioMADE;
                            ``(iv) the agricultural community and 
                        relevant Federal agencies, including the 
                        Department of Agriculture;
                            ``(v) the transportation sector and 
                        relevant Federal agencies, including the 
                        Department of Transportation;
                            ``(vi) other Federal agencies, including 
                        the Department of Commerce, as determined 
                        necessary by the covered facility;
                            ``(vii) Federal education and workforce 
                        development programs, including the National 
                        Science Foundation;
                            ``(viii) institutions of higher education;
                            ``(ix) rural community stakeholders;
                            ``(x) nonprofit organizations;
                            ``(xi) State and local governments; and
                            ``(xii) international bodies with relevant 
                        scientific expertise.
            ``(5) Request for information.--Not later than 90 days 
        after the date of enactment of the Bioindustrial Scale-Up for 
        Supply Chains and Energy Resiliency Act of 2026, the Secretary 
        shall publish a request for information that shall be used by 
        the Secretary to evaluate--
                    ``(A) existing and planned bioindustrial technology 
                maturation facilities in the United States, including 
                facilities with gas fermentation technologies and 
                large-scale fermentation tanks with robust sensor 
                suites;
                    ``(B) best practices for collaboration at those 
                facilities; and
                    ``(C) any other information determined necessary 
                for the development of the strategic plan under 
                paragraph (6).
            ``(6) Strategic plan.--Not later than 180 days after the 
        date of enactment of the Bioindustrial Scale-Up for Supply 
        Chains and Energy Resiliency Act of 2026, the Secretary shall 
        submit to the relevant congressional committees a strategic 
        plan for the implementation of this subsection that includes--
                    ``(A) an assessment of capacity scaling needs to 
                determine what type of additional technology maturation 
                facilities are needed;
                    ``(B) a description of the type, size, and location 
                of each covered facility that the Secretary intends to 
                establish;
                    ``(C) the total number of covered facilities that 
                the Secretary intends to establish;
                    ``(D) the timelines associated with planning and 
                execution of each covered facility, phased over time; 
                and
                    ``(E) a general description of--
                            ``(i) the focus of each covered facility, 
                        including the types of manufacturing equipment, 
                        if any, that are expected to be procured for 
                        each covered facility;
                            ``(ii) how covered facilities will work as 
                        a network to maximize the variety of 
                        bioindustrial products available to be produced 
                        by the network, including how the capabilities 
                        of covered facilities will complement the 
                        capabilities of existing and planned technology 
                        maturation facilities, including those of other 
                        Federal agencies, including the Department of 
                        Commerce and the Department of Defense;
                            ``(iii) how that network will support the 
                        establishment and maintenance of the 
                        bioindustrial manufacturing industrial base;
                            ``(iv) how the Secretary intends to ensure 
                        that data is collected and shared with the rest 
                        of that network, as applicable; and
                            ``(v) how the Secretary intends to 
                        coordinate with other Federal agencies, 
                        including the Department of Commerce and the 
                        Department of Defense, to ensure the effective 
                        use of funds, development of capabilities, and 
                        prioritization of biotechnologies.
            ``(7) Intellectual property protections.--
                    ``(A) Federal employee contributions.--Any 
                intellectual property created by a Federal employee at 
                a covered facility in the performance of the duties of 
                that Federal employee shall be considered to be part of 
                the public domain.
                    ``(B) Other entities.--Any intellectual property 
                created by an individual at a covered facility who is 
                not a Federal employee shall be protected under 
                applicable intellectual property laws, subject to the 
                terms of the contractual agreement that the individual 
                has entered into with the Secretary.
                    ``(C) Data sharing.--To the maximum extent 
                practicable, a covered facility shall establish a 
                secure, interoperable digital system to facilitate data 
                exchange across government, academia, and industry.
            ``(8) Report to congress.--Not later than 1 year after the 
        date of enactment of the Bioindustrial Scale-Up for Supply 
        Chains and Energy Resiliency Act of 2026, and at least once 
        every year thereafter for the following 7 years, the Secretary 
        shall submit to the relevant congressional committees, and make 
        publicly available, a report on the activities carried out 
        under this subsection during the year covered by the report, 
        including the progress made in implementing the strategic plan 
        under paragraph (6), including--
                    ``(A) the number of existing covered facilities;
                    ``(B) the number of additional covered facilities 
                being planned, if any;
                    ``(C) a description of the activities carried out 
                by covered facilities; and
                    ``(D) any collaborations under paragraph (4).
            ``(9) Authorization of appropriations.--There is authorized 
        to be appropriated to the Secretary to carry out this 
        subsection $225,500,000 for the period of fiscal years 2026 
        through 2030.''.

SEC. 4. TECHNICAL CORRECTION.

    The table of contents of the Energy Policy Act of 2005 (Public Law 
109-58; 119 Stat. 594) is amended by inserting after the item relating 
to section 1 the following:

``Sec. 2. Definitions.''.
                                 <all>